Malignant melanoma is a skin cancer that can quickly spread throughout the body.

The company has integrated digital dermascopy method and electrical impedance spectroscopy (EIS) technology in Nevisense View instrument, helping to improve and simplify the diagnostic process for malignant melanoma.

Digital dermascopy provides visual information, while EIS technology uses electrical impulses to detect abnormal cell structures that are expected to result in malignant melanoma.

The new instrument can also simplify the process to carry out skin examinations, as all information from the exam will be saved in the same instrument.

Nevisense View combines EIS, image and patient information as a PDF report for full documentation of the examination.

It includes easy-to-use follow-up functions such as shared screen to compare lesions over time.

SciBase CEO Simon Grant said: “According to a new study, conducted by researchers from Melanoma Institute of Australia and Royal Prince Alfred Hospital in Sydney, the use of EIS can reduce the number of cases that need to be followed up using SDDI by almost half, and may also allow for early detection of malignant melanoma three months earlier than traditional methods.

“Being able to combine these two methods into one product and present it in conjunction with a study that supports our method at the World Congress on Cancers of the Skin in Vienna on August 31 is of course a milestone in the company’s history.”